Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(OTCBB:RGBP) Results From Ongoing Studies Suggest Major Role Of Regen's NR2F6 Target In Controlling Key Immune Functions

|Includes: Regen Biopharma, Inc. (RGBP)

www.smallcapsolutions.com

We can Assist any Publicly Traded Company Gain Greater Exposure Creating Increased Awareness and Liquidity in the Market Place (Retail or Private)

** Contact us for Custom Tailored Plans for Your situation

www.regenbiopharmainc.com (OTCQB:RGBP)

SAN DIEGO, February 17, 2016 /PRNewswire

Regen BioPharma, Inc.'s Immune Checkpoint Inhibitor Found to Stimulate Key Immune System Proteins Interleukin-17 and Interleukin-18

Basically in Layman's Terms

It Kills Cancer Cells/Tumors

The IL-18 protein, also known as the Interferon Gamma Stimulating Factor, plays an essential role in allowing the immune system to kill Cancer[2].

Read More:

http://finance.yahoo.com/news/regen-biopharma-inc-immune-checkpoint-133000434.html

Recent News Items of Interest:

Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product

http://finance.yahoo.com/news/regen-biopharma-submits-application-fda-133000880.html

Regen BioPharma, Inc. and the National Institutes of Health to Collaborate

http://finance.yahoo.com/news/regen-biopharma-inc-national-institutes-133000075.html

Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXelleratehttp://finance.yahoo.com/news/regen-biopharma-inc-receives-fda-133000659.html

We believe Regen is a Long Play with imminent Short Term Gain potential.

They are a "Cutting Edge" Bio Tech - Stem Cell R&D Company that offers exponential growth.

Regen in our opinion will one day be either the Leader in many areas of Stem Cell treatment and/or could be a very attractive Candidate for a Buy Out or Merger.

Areas of Focus are:

Various Cancers and the treatment of - Breast, Liver, Kidney, Prostate

(dCellVax is on the verge of & awaits FDA clearance for Phase I Human/Patient clinical trials for Breast Cancer)

Treatment of Rare Blood Disorders & Diseases (HemaXellerate FDA "Cleared/Approved " for Human/Patient clinical trials (aPlastic Anemia) Phase I to commence soon.

Treatment of Leukemia

Robert E. Kreh

Principal

Small Cap Solutions, LLC

(443) 567-2609

robkreh@smallcapsolutions.com

robkreh@gmail.com

Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at www.otcmarkets.com. Small Cap Solutions, LLC has received $1,000 in cash from a Third Party to be named upon request for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to admin@smallcapsolutions.com or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct. #1 Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile(s) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein.

Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at yahoofinance.com otcmarkets.com Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(s)/Broker Dealer(s) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public.

Additional inquiries available by email to admin@smallcapsolutions.com or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.